Cmxtwenty is a Milwaukee based pharmaceutical company focused on the development of a unique lipid compound to be used as a non-narcotic treatment for pain. Established in November 2004, Cmxtwenty received its initial funding through an SBIR grant from the National Institute on Drug Abuse (NIDA). Since 2007, Cmxtwenty has been funded privately by a network of individual investors. Our lead product, CMX-020, is an analog of arachidonic acid, a common endogenous lipid and one of the most abundant lipids for cell signaling in the brain. Cmxtwenty maintains international patent filings on CMX-020 through 2029. Phase 2 proof-of-concept clinical studies with oral CMX-020 will be completed in early 2016.